Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FILbiowm study of fondazione italiana linfomi

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAngela FerrariMMMichele MerliECEmanuele Cencini

Discussion

Loading...

Member takes

Overview

Observational analysis shows TP53 mutations impact overall survival in Waldenström Macroglobulinemia, suggesting cell-free DNA is a viable detection method.

Key Points

  • TP53 mutations indicate shorter overall survival in Waldenström Macroglobulinemia patients, and 11% had these mutations.
  • Analysis of 279 patients revealed 10% of WM patients had TP53 mutations, linked to variant allele frequencies of 30%.
  • Targeted next-generation sequencing was used to examine paired bone marrow and plasma samples at diagnosis.
  • Implication highlights the potential for non-invasive testing through cell-free DNA for monitoring TP53 mutations in WM patients.

Cite This Study

Ferrari et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db0fhttps://doi.org/10.1182/blood-2025-5318
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation2025
  2. 2Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.2025 · 3 citations
  3. 3Integrative omics analysis of TP53 in multiple myeloma patients2025
  4. 4Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  5. 5Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era2025